118 related articles for article (PubMed ID: 35961282)
21. Evaluation, Validation, and Implementation of the Idylla System as Rapid Molecular Testing for Precision Medicine.
Huang H; Springborn S; Haug K; Bartow K; Samra H; Menon S; Mackinnon AC
J Mol Diagn; 2019 Sep; 21(5):862-872. PubMed ID: 31443844
[TBL] [Abstract][Full Text] [Related]
22. Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm.
De Luca C; Rappa AG; Gragnano G; Malapelle U; Troncone G; Barberis M
J Clin Pathol; 2018 Aug; 71(8):745-750. PubMed ID: 29798838
[TBL] [Abstract][Full Text] [Related]
23. Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens.
Pisapia P; Malapelle U; Roma G; Saddar S; Zheng Q; Pepe F; Bruzzese D; Vigliar E; Bellevicine C; Luthra R; Nikiforov YE; Mayo-de-Las-Casas C; Molina-Vila MA; Rosell R; Bihl M; Savic S; Bubendorf L; de Biase D; Tallini G; Hwang DH; Sholl LM; Vander Borght S; Weynand B; Stieber D; Vielh P; Rappa A; Barberis M; Fassan M; Rugge M; De Andrea CE; Lozano MD; Lupi C; Fontanini G; Schmitt F; Dumur CI; Bisig B; Bongiovanni M; Merkelbach-Bruse S; Büttner R; Nikiforova MN; Roy-Chowdhuri S; Troncone G;
Cancer Cytopathol; 2019 May; 127(5):285-296. PubMed ID: 31021538
[TBL] [Abstract][Full Text] [Related]
24. Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.
Evrard SM; Taranchon-Clermont E; Rouquette I; Murray S; Dintner S; Nam-Apostolopoulos YC; Bellosillo B; Varela-Rodriguez M; Nadal E; Wiedorn KH; Melchior L; Andrew E; Jones M; Ridgway J; Frykman C; Lind L; Rot M; Kern I; Speel EJM; Roemen GMJM; Trincheri N; Freiberger SN; Rechsteiner M
J Mol Diagn; 2019 Nov; 21(6):1010-1024. PubMed ID: 31445213
[TBL] [Abstract][Full Text] [Related]
25. Performance evaluation of the Biocartis Idylla EGFR Mutation Test using pre-extracted DNA from a cohort of highly characterised mutation positive samples.
Grant J; Stanley A; Balbi K; Gerrard G; Bennett P
J Clin Pathol; 2022 Apr; 75(4):241-249. PubMed ID: 33514586
[TBL] [Abstract][Full Text] [Related]
26. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
[TBL] [Abstract][Full Text] [Related]
27. Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.
Melchior L; Grauslund M; Bellosillo B; Montagut C; Torres E; Moragón E; Micalessi I; Frans J; Noten V; Bourgain C; Vriesema R; van der Geize R; Cokelaere K; Vercooren N; Crul K; Rüdiger T; Buchmüller D; Reijans M; Jans C
Exp Mol Pathol; 2015 Dec; 99(3):485-91. PubMed ID: 26407762
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Biocartis IDYLLA ™ cartridge assay with Qiagen GeneReader NGS for detection of targetable mutations in EGFR, KRAS/NRAS, and BRAF genes.
Haiduk T; Brockmann M; Tillmann RL; Pieper M; Lüsebrink J; Schildgen V; Schildgen O
Exp Mol Pathol; 2021 Jun; 120():104634. PubMed ID: 33773991
[TBL] [Abstract][Full Text] [Related]
29. Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform.
Darwanto A; Hein AM; Strauss S; Kong Y; Sheridan A; Richards D; Lader E; Ngowe M; Pelletier T; Adams D; Ricker A; Patel N; Kühne A; Hughes S; Shiffman D; Zimmermann D; Te Kaat K; Rothmann T
BMC Cancer; 2017 May; 17(1):358. PubMed ID: 28532404
[TBL] [Abstract][Full Text] [Related]
30. Ultrarapid
Arcila ME; Yang SR; Momeni A; Mata DA; Salazar P; Chan R; Elezovic D; Benayed R; Zehir A; Buonocore DJ; Rekhtman N; Lin O; Ladanyi M; Nafa K
JTO Clin Res Rep; 2020 Sep; 1(3):. PubMed ID: 33511359
[TBL] [Abstract][Full Text] [Related]
31. Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.
Gao J; Wu H; Wang L; Zhang H; Duan H; Lu J; Liang Z
BMJ Open; 2016 Jan; 6(1):e009532. PubMed ID: 26747035
[TBL] [Abstract][Full Text] [Related]
32. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
Sakai K; Tsurutani J; Yamanaka T; Yoneshige A; Ito A; Togashi Y; De Velasco MA; Terashima M; Fujita Y; Tomida S; Tamura T; Nakagawa K; Nishio K
PLoS One; 2015; 10(5):e0121891. PubMed ID: 25954997
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of
Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A
J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401
[TBL] [Abstract][Full Text] [Related]
34. KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system.
Sadlecki P; Antosik P; Grzanka D; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 Oct; 39(10):1010428317733984. PubMed ID: 28992761
[TBL] [Abstract][Full Text] [Related]
35. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
[TBL] [Abstract][Full Text] [Related]
36. Idylla
Khalifa E; Chapusot C; Tournier B; Sentis J; Marion E; Remond A; Aubry M; Pioche C; Bergeron A; Primois C; Blanchard L; Millière A; Boucheix M; Léger Y; Bairrao M; Brouste V; Martin L; Soubeyran I
J Clin Pathol; 2023 Oct; 76(10):698-704. PubMed ID: 35820776
[TBL] [Abstract][Full Text] [Related]
37. Is the Idylla
De Luca C; Conticelli F; Leone A; Gragnano G; Salatiello M; Galasso P; Pisapia P; Grillo LR; Iaccarino A; Vigliar E; Bellevicine C; Malapelle U; Troncone G
J Clin Pathol; 2019 Sep; 72(9):609-614. PubMed ID: 31110050
[TBL] [Abstract][Full Text] [Related]
38. Rapid EGFR Mutation Detection Using the Idylla Platform: Single-Institution Experience of 1200 Cases Analyzed by an In-House Developed Pipeline and Comparison with Concurrent Next-Generation Sequencing Results.
Momeni-Boroujeni A; Salazar P; Zheng T; Mensah N; Rijo I; Dogan S; Yao J; Moung C; Vanderbilt C; Benhamida J; Chang J; Travis W; Rekhtman N; Ladanyi M; Nafa K; Arcila ME
J Mol Diagn; 2021 Mar; 23(3):310-322. PubMed ID: 33346146
[TBL] [Abstract][Full Text] [Related]
39. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
Hartley CP; Mahajan AM; Selvaggi SM; Rehrauer WM
Cancer Cytopathol; 2017 Nov; 125(11):838-847. PubMed ID: 29024530
[TBL] [Abstract][Full Text] [Related]
40. Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue.
Johnston L; Power M; Sloan P; Long A; Silmon A; Chaffey B; Lisgo AJ; Little L; Vercauteren E; Steiniche T; Meyer T; Simpson J
J Clin Pathol; 2018 Apr; 71(4):336-343. PubMed ID: 28899979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
